Neosplice Therapeutics, Inc.
Publicly observedNew York, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | New York | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Neosplice Therapeutics, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | ZJHHBAXNB7B8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant9 Sept 2026Publicly observed
NIH SBIR/STTR award: Isoform?Resolved Target Discovery and Validation in Cancer
USD 406,500.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant20 Jul 2026Publicly observed
NIH SBIR/STTR award: PROTEOGENOMIC DISCOVERY ENGINE FOR EXPOSING THE EXPOSED: SPLICE SURFACE THERAPEUTIC TARGETS
USD 321,316.00 · National Center for Advancing Translational Sciences · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.